These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 7688827)

  • 1. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.
    Pinter A; Honnen WJ; Tilley SA
    J Virol; 1993 Sep; 67(9):5692-7. PubMed ID: 7688827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
    Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
    J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
    Stamatatos L; Cheng-Mayer C
    J Virol; 1995 Oct; 69(10):6191-8. PubMed ID: 7545244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    McKeating JA; Cordell J; Dean CJ; Balfe P
    Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
    Wu Z; Kayman SC; Honnen W; Revesz K; Chen H; Vijh-Warrier S; Tilley SA; McKeating J; Shotton C; Pinter A
    J Virol; 1995 Apr; 69(4):2271-8. PubMed ID: 7533854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.
    Tilley SA; Honnen WJ; Racho ME; Chou TC; Pinter A
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):461-7. PubMed ID: 1376135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
    McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
    J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
    Sattentau QJ; Moore JP
    J Exp Med; 1991 Aug; 174(2):407-15. PubMed ID: 1713252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    Moore JP; McCutchan FE; Poon SW; Mascola J; Liu J; Cao Y; Ho DD
    J Virol; 1994 Dec; 68(12):8350-64. PubMed ID: 7525988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L; Lim M; Cheng-Mayer C
    AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.
    Yuan W; Bazick J; Sodroski J
    J Virol; 2006 Jul; 80(14):6725-37. PubMed ID: 16809278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
    Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
    J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.